Overview

• Emcure Pharmaceuticals posted a 64% year-on-year rise in consolidated net profit for Q4 FY25, reaching Rs 189 crore.
• Revenue grew 19.5% to Rs 2,116 crore, driven by strong domestic and international performance.
• Shares on the NSE hit a 10% upper circuit, closing at Rs 1,171.50, reflecting investor confidence in the company’s growth trajectory.
• The board approved a final dividend of Rs 3 per equity share for the financial year ending March 31, 2025.
• Emcure is integrating recent European acquisitions and leveraging regulatory approvals to expand its diverse pharmaceutical portfolio globally.